Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Impact of LDL-cholesterol Lowering on Platelet Activation
NCT03331666 · Columbia University · PHASE4 · terminated · last registry update 2021-04-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated Prematurely due to COVID-19” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-17Results posted on the registry: University of Florida, Evolocumab (NCT03096288)
- 2022-02-10Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT05234775)
- 2022-02-10Results posted on the registry: LIB Therapeutics LLC, LIB003 (NCT03847974)
- 2022-01-14Results posted on the registry: Amgen, Evolocumab (NCT02624869)
- 2021-11-24Results posted on the registry: Amgen, Evolocumab + Placebo (NCT03570697)
- 2021-10-11Results posted on the registry: Marja-Riitta Taskinen, Evolocumab (NCT02948777)
- 2021-09-16Also stopped (terminated): Minneapolis Heart Institute Foundation, Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection (NCT03542110)
- 2021-09-01Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran sodium 300 mg + Placebo (NCT05030428)
- 2021-08-20Results posted on the registry: Amgen, evolocumab + placebo (NCT03433755)
- 2021-08-13Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep + Inclisiran (NCT05004675)
- 2021-07-20Phase 3 first posted: Beijing Anzhen Hospital, PCSK9 inhibitors and statins with or without ezetimibe + Statins with or without ezetimibe (NCT04968509)
- 2021-06-29Results posted on the registry: Regeneron Pharmaceuticals, Alirocumab + Placebo (NCT03156621)
- 2021-06-28Phase 3 first posted: Collegium Medicum w Bydgoszczy, Evolocumab + Saline solution (NCT04941105)
- 2021-06-18Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran (NCT04929249)
- 2021-06-15Results posted on the registry: Regeneron Pharmaceuticals, Praluent (NCT03694197)
- 2021-06-15Also stopped (terminated): Regeneron Pharmaceuticals, Praluent (NCT03694197)
- 2021-05-07Results posted on the registry: Regeneron Pharmaceuticals, Praluent (Alirocumab) + Placebo (NCT02957682)
- 2021-05-05Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran (NCT04873934)
- 2021-03-19Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Background lipid lowering therapy (NCT04807400)
- 2021-03-19Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04806893)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797104)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04798430)
- 2021-03-15Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT04797247)
- 2021-03-10Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep + evolocumab (NCT04790513)
- 2021-02-21Phase 3 first posted: Novartis Pharmaceuticals, inclisiran sodium + Placebo (NCT04765657)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision